<code id='8B65B21350'></code><style id='8B65B21350'></style>
    • <acronym id='8B65B21350'></acronym>
      <center id='8B65B21350'><center id='8B65B21350'><tfoot id='8B65B21350'></tfoot></center><abbr id='8B65B21350'><dir id='8B65B21350'><tfoot id='8B65B21350'></tfoot><noframes id='8B65B21350'>

    • <optgroup id='8B65B21350'><strike id='8B65B21350'><sup id='8B65B21350'></sup></strike><code id='8B65B21350'></code></optgroup>
        1. <b id='8B65B21350'><label id='8B65B21350'><select id='8B65B21350'><dt id='8B65B21350'><span id='8B65B21350'></span></dt></select></label></b><u id='8B65B21350'></u>
          <i id='8B65B21350'><strike id='8B65B21350'><tt id='8B65B21350'><pre id='8B65B21350'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:knowledge    Page View:22
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In